Dr. Rebecca Zash -"Integrase Inhibitors not linked to adverse birth outcomes"

July 27, 2017
Dr Rebecca Zash

Photo Credit: Steve Forrest/Workers' Photos/IAS

HU CFAR Reproductive Health for HIV-Affected Populations Scientific Working Group Leader, Dr. Rebecca Zash presented study results from Botswana investigating first line antiretroviral therapy option Dolutegravir.  The integrase inhibitor has been prescribed more frequently during pregnancy and is not linked to any increase in adverse birth outcomes.  The results of the large scale survey with data from eight maternity wards throughout Botswana was presented alongside results from a study in France.

Read more: http://www.aidsmap.com/Integrase-inhibitors-not-causing-higher-rates-of-adverse-birth-outcomes-Botswana-and-French-studies-show/page/3159279/